Diabetes therapies in hemodialysis patients: Dipeptidase-4 inhibitors

Table 1 Seven dipeptidase-4 inhibitors

Dose and pharmacokinetics	Sitagliptin	Vildagliptin	Alogliptin	Linagliptin	Teneligliptin	Anagliptin	Saxagliptin
Daily dose (mg)	25	50	6.25	5	20	100	2.5
Molecular weight (Da)	523.32	303.4	461.51	472.54	628.86	383.45	333.43
Bioavailability	87%	85%	100%	30%	Unknown	73.2%	Unknown
Protein binding	38.0%	9.3%	28.2%-38.4%	> 80%	77.6%-82.2%	37.1%-48.2%	Negligible
Cmax (vs healthy volunteer)	1.4 fold	1.4 fold	3.2 fold	1.5 fold	1.0 fold	1.4 fold	Unknown
AUC (vs healthy volunteer)	4.5 fold	2.0 fold	3.8 fold	1.5 fold	1.5 fold	3.2 fold	2.1 fold
t1/2 (h) (vs healthy volunteer)	2.2	2	Unknown	Unknown	1.0 fold	0.9 fold	Unknown
Dialyzability	13.50%	3.00%	7.20%	Unknown	15.60%	Unknown	4.00%

Cmax, AUC and t_1/2 were measured under different dose conditions. AUC: Area under the curve.